Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Glenmark Ups Respiratory Play But Is The Digihaler Disruptive?

Executive Summary

Glenmark Pharmaceuticals Ltd., which is building its global respiratory play, appears to be betting big on its new next-generation digital inhaler that the India firm underscores is meaningful innovation that patients can afford. The jury, though, appears to be still out on whether India’s first digital dose inhaler (DDI) can help move the adherence needle.


Related Content

Glenmark’s Digital Asthma Inhaler: Is It Really A Roaring Success?
Mylan's Generic Advair FDA Filing Puts Added Squeeze On GSK
Seretide Competition Builds Up But Substitutability Holds Key?
Watch The Indian Respiratory Space: Cipla, GSK At Work
Glenmark gets first generic approvals for Advair MDI